Author of

• 28971

  +

  Lunch & Poster Display session (ID 58)

  • Event: ELCC 2019
  • Type: Poster Display session
  • Track:
  • Presentations: 1
  • Moderators:
  • Coordinates: 4/11/2019, 12:30 - 13:00, Hall 1

  • 29128

    +

    197P - Effect of surgical treatment on the survival in patients with malignant pleural mesothelioma (ID 482)

    12:30 - 13:00  |  Presenting Author(s): Renata Baez-Saldana
    • Abstract
    • Slides

    Background
    

    In patients with malignant pleural mesothelioma (MPM) chemotherapy is the only treatment modality that has been shown to improve survival. Surgery, by either pleurectomy/decortication (P/D) or extrapleural pneumonectomy (EPP) can be an option of treatment in patients with early stage disease and good functional status, nevertheless, this modality remains questionable. The aim of this study was to evaluate the effect of surgical treatment on the survival in patients with MPM.

    a9ded1e5ce5d75814730bb4caaf49419 Methods
    

    Case series of patients with histologically proven MPM between January 2012 and Jun 2015 were reviewed retrospectively. The variables analyzed were: age, sex, asbestos exposure, smoking history, biomass exposure, performance status with ECOG scale, staging and type of treatment. Univariate and multivarite analyses were performed using the Cox regression model. Survival functions were estimated using the Kaplan-Meier statistics. The decision to perform either P/D or EPP was on the basis surgeon’s preference.

    20c51b5f4e9aeb5334c90ff072e6f928 Results
    

    There were 122 cases of MPM; 71% were males and the media age at diagnosis was 63 years. Twenty (16.4%) of the cases received surgery, 8 EPP, 8 P/D, and 4 were unresectable at the moment of the surgery. The 30-day mortality was 5%, one patient after EPP. The median survival in all cases was 8.6 months, while in the surgical vs no surgical group was 15.8 vs 7.2 months respectively (p < 0.05). In comparision to no surgery treatment, surgery alone was associated with significant improvement in survival [adj HR 0.20 (95%CI: 0.07-0.56). At multivariate analysis independent significant predictors of survival were surgery [adj HR 0.21 (95%CI: 0.06-0.71), beign female [adj HR 0.49 (95%CI: 1.06-4.48), chemotherapy [adj HR 0.22 (95%CI: 0.07-0.70), stage early vs advanced [adj HR 0.47 (95%CI: 0.22-1.04) and ECOG < 2 [adj HR 0.21 (95%CI: 0.06-0.76).

    fd69c5cf902969e6fb71d043085ddee6 Conclusions
    

    Our data suggest relative advantage of surgery on survival. Patients who received surgery had better survival than patients who were treated with chemotherapy or palliative care alone.

    b651e8a99c4375feb982b7c2cad376e9 Legal entity responsible for the study
    

    Instituto Nacional de Enfermedades Respiratorias.

    213f68309caaa4ccc14d5f99789640ad Funding
    

    Has not received any funding.

    682889d0a1d3b50267a69346a750433d Disclosure
    

    All authors have declared no conflicts of interest.

    cffcb1a185b2d7d5c44e9dc785b6bb25

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.